Drupal.behaviors.print = function(context) {window.print();window.close();}>
Rosetta Receives Clearance to Sell miRNA Diagnostics in NY State
January 06, 2011
Rosetta Receives Clearance to Sell miRNA Diagnostics in NY State
With the approval, Rosetta can now sell its suite of three microRNA-based tests in all 50 states.
Full-text access for premium subscribers only.
Existing premium subscribers
login here
.
New to GenomeWeb?
Register here
quickly.
Related Stories
After Raising Cash, Rosetta Aims to Restart R&D Efforts, Get Additional Medicare Approvals
October 4, 2012 / Gene Silencing News
After Medicare Nod for CUP Diagnostic, Rosetta Aims to Get Coverage for Other miRNA Tests
May 24, 2012 / Gene Silencing News
Rosetta Genomics, Prime Health Reach Deal for Coverage of MiRview Mets2 Assay
May 20, 2013 / GenomeWeb Daily News
Rosetta, Precision Therapeutics Reach Co-marketing Deal for miRview mets2 Assay
July 24, 2012 / GenomeWeb Daily News
Rosetta Publishes Data on Cancer of Unknown Primary Origin Test
May 31, 2012 / Gene Silencing News